{
  "docId": "019de076-928b-754c-8bda-49c7fed3154d",
  "docSlug": "58a8f830d3c9f9a6fedd64a0d2a10227",
  "documentTitle": "ATAI | Investor Presentation Deck | 34 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 34,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Slide 32 of the deck.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-928b-754c-8bda-49c7fed3154d/32",
  "deckHref": "/decks/019de076-928b-754c-8bda-49c7fed3154d",
  "deckJsonHref": "/decks/019de076-928b-754c-8bda-49c7fed3154d.json",
  "deckAnchorHref": "/decks/019de076-928b-754c-8bda-49c7fed3154d#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.52,
        "y": 0.242
      },
      "kind": "list",
      "text": "Target engagement demonstrated: Dose-dependent increases in qEEG beta power. Safe & well-tolerated: Well-tolerated with no dose limiting toxicities. Sedation comparable to placebo: Sedation in-line with placebo.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50d74890-bd1a-4579-9a29-a464257bb3eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.46,
        "x": 0.035,
        "y": 0.242
      },
      "kind": "paragraph",
      "text": "COMPLETED PHASE 1 TRIAL",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46a31263-e18c-4e40-b71c-c989375f5529",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.39,
        "x": 0.035,
        "y": 0.925
      },
      "kind": "source-note",
      "text": "Note: PK / PD = Pharmacokinetic / Pharmacodynamic; qEEG = Quantitative electroencephalography; BID = Twice daily",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8c19775-0727-4050-9cf6-8c8320507f6b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.028,
        "w": 0.765,
        "x": 0.028,
        "y": 0.115
      },
      "kind": "title",
      "text": "Demonstrated a rapid and dose-dependent PK/PD effect along with a favourable safety profile",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90bf9827-7c55-4ee8-bc69-d12d0a41a975",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.678,
        "x": 0.028,
        "y": 0.065
      },
      "kind": "title",
      "text": "Phase 1 Study: GRX-917 Trial Design & Results Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "520aea89-b43f-4a50-a0e1-8b07ebe1aa92",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 34,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "c65cfc1b-596e-44b3-abf6-776a6539dcbf",
      "evidence": "The deck emphasizes the need for effective treatments",
      "position": 0,
      "objective": "Highlight the importance of addressing mental health disorders",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 34,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "7657d45c-02c7-40ab-9afc-a644dc2ed2c5",
      "evidence": "The deck follows a structure that aligns with the Golden Circle",
      "position": 1,
      "objective": "Explain the company's approach and solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}